Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control treatment. In addition, it offers various gauge laser applicators and introducers, as well as provides temperature and treatment monitoring devices. The company has a strategic partnership with ClearPoint Neuro Inc. for the development of ClearPoint Prism, a Neuro Laser Therapy System. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.…
SKFs styrelse tar nästa steg i noteringen av SKF Vertevo och kallar till extra bolagsstämma
Clinical Laserthermia Systems (STO: CLS-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector.
The shares were at 1.588 SEK on 20 November 2026, down 82.9% over 52 weeks. Its 52-week range is 1.502 SEK to 9.980 SEK: the price is 84.1% below the high and 5.7% above the low.
Its market capitalisation is 77.05M SEK.
Clinical Laserthermia Systems reports return on equity of -59.7%, an operating margin of -278.0% and revenue down 18.3% year over year.
It holds more cash than debt, a net cash position of 3.87M SEK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 5.500 SEK is 246.3% above the current price.
No upcoming events tracked.